Company
Headquarters: Tonghua, China
Employees: 2,723
CN¥20.65 Billion
CNY as of Jan. 1, 2024
US$2.91 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
| AbbVie | $285.06 B |
| Roche | $240.44 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. Its lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, and insulin lispro; antidiabetic drugs; and oral hypoglycemic drugs, as well as Gan Shulin pens, blood glucose meters, and other medical devices. It offers building materials. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Tonghua Dongbao Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600867 wb_incandescent